Physician profile
Jonathan Bernstein
NPI 1669565982
$112,113.91
in general payments reported to CMS, 2019-2025
25 companies · $13K in 2025
The $13K reported for 2025 was more than what 88% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $3,114 · 2021: $8,820 · 2022: $4,596 · 2023: $12K · 2024: $12K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $2,367 · Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,070.75 |
| Travel and Lodging | $2,366.73 |
| Food and Beverage | $2,270.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29,139.85 | 2019-2025 | |
| Bioverativ Therapeutics INC. | $18,252.73 | 2019 | |
| Biomarin Pharmaceutical INC. | $16,255.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $15,696.37 | 2019-2024 | |
| Novo Nordisk INC | $10,652.63 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $6,952.17 | 2019 | |
| Octapharma USA, INC. | $4,649.31 | 2019 | |
| Aptevo Therapeutics INC | $3,996.32 | 2019 | |
| Agios Pharmaceuticals, INC. | $2,122.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,101.79 | 2022-2023 | |
| Bio Products Laboratory USA, INC. | $576.89 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $406.00 | 2023 | |
| Zoll Medical Corporation | $400.00 | 2023 | |
| Tersera Therapeutics LLC | $393.00 | 2023 | |
| Shire North American Group INC | $344.03 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $282.51 | 2019-2021 | |
| Genentech USA, INC. | $261.53 | 2019-2022 | |
| Genentech, INC. | $149.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 | |
| Y-Mabs Therapeutics, INC. | $97.30 | 2023 | Danyelza |
| Pfizer INC. | $90.51 | 2025 | |
| Sobi, INC | $53.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $50.59 | 2021 | |
| Csl Behring | $42.88 | 2019 | |
| Glaxosmithkline, LLC. | $21.72 | 2025 | Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.